D-0163-2025 Class II Terminated
FDA drug recall D-0163-2025 was initiated by PD-Rx Pharmaceuticals, Inc. on Dec 4, 2024 and is designated Class II. Reason for recall: CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit The recall status is terminated (terminated Mar 21, 2025). Affected quantity: 70, 90-count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 1, 2025
- Initiation Date
- Dec 4, 2024
- Termination Date
- Mar 21, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 70, 90-count bottles
Product description
DULoxetine DR USP, 30 mg, 90-count bottle, Rx Only, Packaged by: PD Rx Pharmaceuticals Inc, Oklahoma City, OK 73127, NDC: 43063-877-90
Reason for recall
CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit
Distribution pattern
Distributed within US: FL, MS, WI
Code information
Lot # I24E77, A24E49, Exp Date: 04/30/25; J23C50, J23C97, L23B39, L23E98, Exp Date: 01/31/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0163-2025
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026